Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867212 · ClinicalTrials.gov registry record
Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
A clinical trial, sponsored by Kelley-Ross & Associates.
- Completed
- Registry status
- 50
- Enrollment target
NCT05867212: Completed study, sponsored by Kelley-Ross & Associates.
NCT05867212 is a clinical trial that has completed, run by Kelley-Ross & Associates. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05867212 has completed, sponsored by Kelley-Ross & Associates.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting. The main question it aims to answer are: * Is the program feasible and acceptable at the end of 1 year of operations? * What are the facilitators and barriers of the program? Participants who want to start the FDA approved cabotegravir long acting injectable medication for PrEP will have the option participating in surveys and a review of their electronic health records. Medication will be administered based on FDA approved labeling guidelines and their PrEP care will be part of standard of care per CDC. Pharmacists who want to provide the service to their patients will have the option of participating in surveys pre and post implementation.
Primary Outcome
Percentage of participants recruited into PrEP care at initiation
Interventions
- DRUG Cabotegravir Injection [Apretude]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-05-13 |
| Est. Completion | 2025-04-30 |
What the finished NCT05867212 record still lists
NCT05867212 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cabotegravir Injection [Apretude] is the first listed.
NCT05867212 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05867212 about?
NCT05867212 is a clinical study titled "Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.". The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting. The main question it aims to answer are: * Is the program feasible and accept...
What is the current status of trial NCT05867212?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2023-05-13. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05867212?
The interventions under investigation include: Cabotegravir Injection [Apretude] (DRUG).
Who is sponsoring clinical trial NCT05867212?
This trial is sponsored by Kelley-Ross & Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI